Virologists demonstrate how poxviruses defeat the body's host immune defenses

NewsGuard 100/100 Score

Smallpox virus, which killed millions of humans through the ages, ranks among the world's most feared bioterrorism agents. Human monkeypox continues to occur sporadically in remote African villages.

In a new report, virologists from the School of Medicine at The University of Texas Health Science Center at San Antonio and their collaborators at Oklahoma State University demonstrate how poxviruses such as smallpox defeat the body's host immune defenses. The implications extend beyond viral infections to cancer therapy, said senior author Yan Xiang, Ph.D., associate professor in the Department of Microbiology and Immunology, UT Health Science Center.

Dr. Xiang and colleagues revealed how a molecule on the poxviruses defeats a host restriction factor called SAMD9 in humans and animals. In addition to protecting against viruses, SAMD9 suppresses tumors, and mutations in the human SAMD9 gene are responsible for a life-threatening cancer called normophosphatemic familiar tumoral calcinosis. SAMD9 is also implicated in myeloid leukemias and lung cancer.

"There is an 'arms race' occurring between pathogens (disease-causing agents) and their hosts," Dr. Xiang said. "To survive in their hosts, many pathogens utilize specific inhibitors of the host restriction factors. SAMD9 is an evolutionally conserved immune barrier, but it has been successfully overcome by diverse poxviruses." First author of the study is Xiangzhi Meng, Ph.D., an assistant professor in microbiology and immunology at the Health Science Center.

The discovery was described in December in Proceedings of the National Academy of Sciences.

Source: University of Texas Health Science Center at San Antonio


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New trials show promise for immune checkpoint blockers in early-stage lung cancer